Type: Public
On the web: http://www.acadia-pharm.com

ACADIA Pharmaceuticals puts genes and drugs together to fight disease. The development-stage company uses its proprietary R-SAT technology to identify and evaluate genomic targets for drug therapies, primarily for central nervous system disorders. ACADIA hopes its lead drug candidate pimavanserin will effectively treat psychosis in patients with Parkinson's disease. In partnership with eye-care heavyweight Allergan, ACADIA is also developing therapies for glaucoma and chronic pain. Other development targets include neurological indications such as insomnia and schizophrenia.

Key numbers for fiscal year ending December, 2007:
Sales: $7.6M
One year growth: (7.0%)
Net income: ($56.4)M

Officers:
Chairman: Leslie L. Iversen
CEO and Director: Uli Hacksell
SVP Business Development: Biopharmaceuticals & Biotherapeutics

Competitors:
AstraZeneca
Eli Lilly
Pfizer